# Novo Nordisk’s Expansion in Indonesia to Boost Pharmaceutical Market Attractiveness

- Link: https://www.thailand-business-news.com/asean/indonesia/156109-novo-nordisks-expansion-in-indonesia-to-boost-pharmaceutical-market-attractiveness
- Published: 2024-08-14T11:21:00+07:00
- Author: News Desk

**Key View**

 * Indonesia’s pharmaceutical market will continue to represent a high-growth opportunity
   for multinational drugmakers. 
 * Bolstering domestic pharmaceutical production will bode well for Indonesia’s 
   export potential. 
 * Weak intellectual property framework and business climate could dissuade investment
   in pharmaceutical sector and create a challenging environment for drugmakers.

**Indonesia’s pharmaceutical market will continue to represent a high-growth opportunity
for multinational drugmakers. **On July 9 2024, Novo Nordisk signed an agreement
with Indonesia’s state-owned pharmaceutical company Bio Farma to package insulin
in the country. Under the memorandum of understanding, Novo Nordisk will bring in
its know-how in diabetes care and insulin manufacturing while Bio Farma will contribute
its local facilities. The success of this partnership will position Indonesia as
an attractive destination for other global pharmaceutical companies looking to expand
their operations in Southeast Asia. Indeed, demonstrating the ability to successfully
collaborate on large-scale pharmaceutical projects can enhance the market’s reputation
and attract further investment in biopharmaceutical research and development.

ADVERTISEMENT

 Indonesia’s pharmaceutical industry has shown significant growth and development
over the past few decades. It is one of the largest in Southeast Asia and continues
to expand due to various factors, including a growing population, increased healthcare
spending and government initiatives. Moreover, ageing population is another critical
factor, with approximately 15% of Indonesia’s population expected to be over the
age of 60 by 2030. This demographic shift will drive demand for chronic disease 
medications and specialised healthcare products. Indonesia has seen an increase 
in the prevalence of diabetes with an estimated 19mn people suffering from this 
chronic disease. This is expected to rise to an estimated 28.6mn people by 2045.
Additionally, ongoing investments in healthcare infrastructure and digital health
solutions, which was accelerated by the Covid-19 pandemic, are poised to further
boost the pharmaceutical industry. 

Novo Nordisk, the Danish pharmaceutical giant, is making significant strides in 
Indonesia, a market ripe for expansion in the healthcare sector. By establishing
a stronger presence in this Southeast Asian nation, Novo Nordisk aims to meet the
increasing demand for diabetes and obesity treatments. Indonesia’s growing middle
class and rising prevalence of lifestyle-related diseases create a fertile ground
for pharmaceutical companies seeking to enhance healthcare standards and capture
new market shares.

### Related**Posts**

###  󠀁[Offering incentives for companies on the Green List with the IDX Green Equity designation](https://www.thailand-business-news.com/asean/indonesia/331229-offering-incentives-for-companies-on-the-green-list-with-the-idx-green-equity-designation)󠁿

###  󠀁[Indonesia Representative Offices: What They Can and Cannot Do](https://www.thailand-business-news.com/asean/324537-indonesia-representative-offices-what-they-can-and-cannot-do)󠁿

###  󠀁[Which Sector-Specific Licenses Do Foreign Investors Need in Indonesia?](https://www.thailand-business-news.com/asean/328338-which-sector-specific-licenses-do-foreign-investors-need-in-indonesia)󠁿

###  󠀁[Weekend Long Read: Why emerging economies in Asia face a tougher road to growth](https://www.thailand-business-news.com/economics/329802-weekend-long-read-why-emerging-economies-in-asia-face-a-tougher-road-to-growth)󠁿

The company’s expansion strategy focuses on local partnerships and investments, 
which are essential to navigate Indonesia’s complex regulatory landscape. This approach
not only facilitates smoother market entry but also fosters collaboration with local
healthcare providers. By working closely with stakeholders, Novo Nordisk is committed
to developing tailored solutions that cater to the unique health challenges faced
by the Indonesian population, thereby enhancing accessibility to critical medications.

In doing so, Novo Nordisk not only strengthens its market position but also contributes
to elevating the overall pharmaceutical market appeal in Indonesia. As more global
companies follow suit, the nation stands poised for a healthcare transformation,
promising improved health outcomes and a robust pharmaceutical ecosystem that benefits
patients and providers alike.
[Read More](https://www.fitchsolutions.com/bmi/pharmaceuticals/novo-nordisk-expansion-indonesia-will-increase-pharmaceutical-market-appeal-07-08-2024)